Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.

doi:10.1038/s41392-026-02994-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.

Signal transduction and targeted therapy - 28 Aug 2026

Liu Yu-Tao, Tang Le, Han Xiao-Hong, Song Zhi-Yi, Liu De-Ruo, Cheng Gang, Xiao Wen-Hua, Zhang Shu-Cai, Hu Yi, Zhang Li, Liu Jun-Feng, Wang Jun, Dong Gui-Lan, Shi Yuan-Kai

Abstract excerpt

This multi-center, double-blind, placebo-controlled, randomized phase 3 trial (ICWIP) assessed the efficacy and safety of 3-year icotinib adjuvant treatment versus placebo in patients with completely resected stage II-IIIA epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma who had completed four cycles of adjuvant chemotherapy (NCT02125240). Eligible patients were randomly assigned 1:1 to receive...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
Chemotherapy, Adjuvant
Crown Ethers
Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 42660909
DOI: 10.1038/s41392-026-02994-w
PMCID: PMC13522608

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.